?Recently the Journal of Clinical Oncology, published finding that persons heterozygous for the CHEK2*1100delC germline mutation not only have a higher risk of breast cancer, but also a much higher risk for other cancers as well.
CHEK2 is a cell-cycle checkpoint regulator. The study involved data from 86,975 individuals between 2003 and 2010. Among these, 2,442 developed breast cancer, and 6,635 developed other cancers.
The investigators concluded that “CHEK2*1100delC heterozygosity is associated with 15% to 82% increased risk for at least some cancers in addition to breast cancer. This included stomach, kidney, prostate cancers and sarcomas?.
Asian Cancer Institute offers services of Precision and Molecular Oncology headed by Dr Purvish Parikh.